Track market-moving stories before they get noisy

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.

A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading. The selloff is unfolding even as Amgen posted a positive Phase 3 readout of its own in small cell lung cancer, an unusual split that captures how brutally the market can price competitor risk in biotech.

Amgen stock is down 10% to $394.38 at midday, interrupting a gain of 23% year to date (YTD) heading into the session. The move carries added weight because Amgen holds the fourth-largest position in the Dow Jones Industrial Average, so today’s decline pressures that index alongside health care specifically.

Meanwhile, Eli Lilly (NYSE:LLY) shares are down 2% to $1,124.77 on read-through concerns about its own Lp(a) program. As for Novartis stock, it’s tumbling 14% to $137.63 on Tuesday afternoon. The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down 0.37%, so today’s pharma-sector pain isn’t washing across the broad tape. That gap between the biotech names and the benchmark tells you the market is pricing pipeline risk at the sector level.

Pelacarsen Miss Rattles the Lp(a) Class Novartis said last Thursday that pelacarsen, an experimental heart drug developed with Ionis Pharmaceuticals, failed to reduce cardiovascular risk in a late-stage trial. The Novartis 8,323-patient Phase III study lowered Lp(a) levels while missing its primary composite endpoint covering cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization.

Citi analysts said the Lp(a) hypothesis has been weakened, with additional data needed to establish whether the shortfall came from the drug’s mechanism, the trial’s design, or the underlying idea that lowering Lp(a) reduces cardiovascular risk. Amgen and Eli Lilly are both developing Lp(a)-lowering therapies using different technical approaches, so a class-defining failure at a rival forces investors to reweight the odds on every remaining program.

Amgen’s Own Trial Delivered a Win Here’s the wrinkle the market is missing. Amgen also announced this morning that its Phase 3 DeLLphi-305 study met its primary endpoint, showing a statistically significant improvement in overall survival for IMDELLTRA. AstraZeneca (NASDAQ:AZN) partly funded the study and supplied Imfinzi, the comparator in the trial.

Amgen’s IMDELLTRA-plus-Imfinzi regimen is being studied as a first-line maintenance treatment in extensive stage small cell lung cancer, one of the toughest settings in oncology. The readout arrived with hard survival data, an endpoint that carries commercial weight immediately, while a mechanistic Lp(a) result needs another round of confirmation.

Amgen’s cholesterol franchise still matters here. Repatha, its PCSK9 inhibitor, generated Q1 2026 revenue of $876 million on 34% year over year (YoY) growth and 35% volume growth, making it one of Amgen’s fastest-growing brands. Its longer-dated Lp(a) bet, Olpasiran, sits in the Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial, and it’s now the pipeline asset most exposed to today’s class re-rating, according to Amgen.

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) carries Amgen and Eli Lilly as major holdings. A same-day selloff in both names weighs on the fund, even though Novartis isn’t a listed component of the ETF.

Scorecard on the Session Ticker Session Move YTD AMGN -10% +21% LLY -2% +5% NVS -14% -0.76% The gap between the size of Amgen stock’s decline and the modest moves elsewhere shows the market is treating today as a program-level revaluation for the Lp(a) class. Amgen’s YTD anchor is included because the interrupted rally frames the setback in the context of what had been a strong year.

What to Watch Next Amgen stock is being punished for a competitor’s failed trial on the same morning its own trial succeeded, and holding both facts at once is the whole exercise. A pipeline is priced on expected approvals, and the pelacarsen miss lowers the odds on the Olpasiran program Amgen has invested years in. The DeLLphi-305 readout, however, sits closer to commercialization and delivered concrete survival data.

Eli Lilly stock’s shallower decline is a reminder that these are different molecules at different stages, and a class-wide selloff prices them as if they were the same bet. Lilly’s VERVE-102 base editor showed a single dose reduced PCSK9 by up to 88% and LDL-C by up to 62% with durable effects, a mechanism distinct from pelacarsen’s antisense approach. Whether that mechanistic distance ultimately shields Lilly’s cardiovascular program depends on how the Lp(a) hypothesis holds up in the next set of trial readouts across the industry.

Investors sizing their exposure to large-cap pharma may want to keep their positions moderate until follow-up commentary lands from cardiology leaders, since the distinction between a failed drug and a failed idea can’t be settled from a single topline result. Moreover, traders can watch for Amgen’s presentation at the 2026 Wells Fargo Healthcare Conference as the next scheduled catalyst that could reframe the Lp(a) narrative.

Contact [email protected] for any questions or corrections.

IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.

Continuum Advisory LLC lowered its position in Danaher Corporation (NYSE:DHR – Free Report) by 87.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 481 shares of the conglomerate’s stock after selling 3,498 shares during the period. Continuum Advisory LLC’s holdings in Danaher were worth $92,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Main Street Group LTD purchased a new stake in shares of Danaher in the 1st quarter worth about $25,000. N.E.W. Advisory Services LLC purchased a new position in Danaher during the 2nd quarter valued at about $25,000. JPL Wealth Management LLC purchased a new position in Danaher during the 3rd quarter valued at about $25,000. WFA of San Diego LLC acquired a new position in Danaher during the second quarter worth about $26,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Danaher in the fourth quarter valued at about $27,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 0.1% Shares of DHR opened at $207.46 on Tuesday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a market capitalization of $145.84 billion, a PE ratio of 36.85, a price-to-earnings-growth ratio of 2.59 and a beta of 0.78. The stock has a fifty day moving average of $202.03 and a two-hundred day moving average of $192.15. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter in the previous year, the business earned $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, analysts forecast that Danaher Corporation will post 8.53 EPS for the current year. Analysts Set New Price Targets Several analysts have recently commented on DHR shares. DZ Bank began coverage on shares of Danaher in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target on the stock. HSBC reduced their target price on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Guggenheim lowered their target price on Danaher from $235.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Piper Sandler assumed coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target for the company. Finally, Wells Fargo & Company reduced their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Get Our Latest Stock Report on Danaher

About Danaher (Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Recommended Stories Five stocks we like better than Danaher 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Even though major U.S. stock market indexes sit near all-time highs, it's possible to find beaten-down companies worth investing in. Consider Medtronic (MDT -1.89%) and MercadoLibre (MELI -2.63%), both leaders in their respective fields. These corporations have faced some challenges, but they remain excellent buy-and-hold options, despite lagging the market lately. Let me explain.

Image source: Getty Images.

1. Medtronic After spending most of the first half of the year moving south, Medtronic has been rebounding over the past three months. The company's financial results have something to do with that. Take the medical device specialist's first-quarter 2027 update for the period ended July 31. Medtronic’s revenue jumped 13.7% year over year -- a strong showing for the company -- to $9.8 billion. The healthcare leader's adjusted earnings per share (EPS) were $1.45, up 15.1% year over year. Medtronic also raised its revenue growth and EPS guidance for its full fiscal year 2027.

It was a beat-and-raise quarter for the company, which explains why its shares jumped after its earnings release. Still, Medtronic stock is down 2% year to date as of writing, while the S&P 500 has gained 12%. At current levels, the stock might be a steal, especially for investors focused on the long game. Medtronic is riding the wave of several growth drivers, will benefit from others in the medium term, and is also working to improve margins.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

-1.89

%) $

-1.78

Current Price

$

92.39

Right now, the company's cardiac ablation (a procedure that treats irregular heartbeats) solutions are doing much of the heavy lifting, thanks to innovative products it has launched in this niche in recent years. In the company's first quarter, cardiac ablation solutions revenue jumped 88% year over year.

Further, over the next few years, Medtronic should see its Hugo robotic-assisted surgery system gain traction and begin meaningfully contributing to its financial results, especially given the large addressable market in this field. And the company's planned separation of its diabetes care segment should help boost margins, since this unit has lower operating margins. Medtronic looks well-positioned to continue posting solid financial results while maintaining its dividend program.

The company has raised its payouts for 49 consecutive years, an impressive achievement that puts it close to joining the ranks of Dividend Kings, or corporations with at least 50 consecutive annual payout increases. Medtronic is an excellent buy-and-hold option for long-term income seekers.

2. MercadoLibre MercadoLibre has faced increased competition in the e-commerce market in South America. The company has responded by making significant investments in the business that are currently harming profits and margins. For instance, MercadoLibre has expanded free shipping offerings (by lowering the threshold for eligible transactions) in some markets. The e-commerce specialist is also doubling down on its fintech ambitions.

MercadoLibre is expanding credit card offerings across various regions, an initiative that is reducing net income due to expected credit loss provisions. In the second quarter, MercadoLibre's revenue grew by almost 50% year over year to $10.2 billion. But the company's EPS dropped to $9.19, down from the $10.31 reported in the year-ago period.

Despite the challenges -- and the reduced bottom line -- MercadoLibre is a great stock to buy. Here are three reasons why. First, MercadoLibre's initiatives, including expanded free shipping, have worked wonders for other e-commerce specialists by boosting gross merchandise volume and revenue. MercadoLibre has also benefited from similar efforts in the past, and its most recent attempts are already positively impacting financial results.

Premium Feature

Moneyball Superscore

86/100

Today's Change

(

-2.63

%) $

-52.11

Current Price

$

1,926.25

Second, the e-commerce leader's efforts should expand its ecosystem and competitive moat. MercadoLibre benefits from network effects and high switching costs. A larger pool of customers and merchants, combined with broader fintech offerings, can strengthen the company's moat. Third, there is a vast runway for growth in the markets where MercadoLibre operates. The company points out, for instance, that a substantial percentage of people in some of the regions where it does business are underbanked.

MercadoLibre will also benefit from the continued growth of the e-commerce market. The stock is down 18% over the past year, but the company's future seems bright. Investors should consider initiating a position before the stock bounces back.

Medtronic’s Stars Are Aligning for a Price RecoveryMedtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.

Speaking at the Wells Fargo Healthcare Conference, Chairman and Chief Executive Officer Geoff Martha said medical technology is benefiting from innovations that can improve outcomes while potentially lowering costs and expanding patient access. He described AI and robotics as “force multipliers” that enable the company to diagnose conditions earlier and personalize treatment at scale.

Get Medtronic alerts:

Medtronic Bottoms, Healthy Rebound AheadMartha said Medtronic’s AI applications are centered on structured physiological, device and procedure data rather than broad large-language-model applications. He pointed to GI Genius, the company’s AI-supported colonoscopy technology, as an example. In the U.S., he said the technology is becoming a standard of care after clinical trials found that 25% to 50% of polyps could be missed even at leading centers. He also cited its use in India, where less-experienced physicians were able to achieve diagnostic results comparable to those in the U.S.

Limited ACA Exposure, China Stabilization Addressing concerns around healthcare policy changes, Martha said Medtronic has limited exposure to Affordable Care Act-related programs. He said the company’s procedure mix is largely acute rather than elective, with approximately two-thirds of its payer mix tied to Medicare, 25% to commercial insurance and less than 10% to Medicaid. ACA-related programs account for less than 1% of Medtronic’s global revenue, he said.

3 Reasons Analysts Love DexComIn China, Chief Financial Officer Thierry Piéton said Medtronic’s revenue exposure has fallen to between 5% and 6% following volume-based procurement, or VBP, changes. However, he said the company believes the impact of VBP is now largely behind it and that China has returned to a more normal operating environment. Martha said Medtronic remains committed to the country, which he characterized as a profitable growth market as the government expands access to higher-end healthcare.

First-Quarter Growth and Franchise Performance Piéton said Medtronic reported first-quarter growth of 13.7% including an extra week in the period, or about 7% after adjusting for that extra week. He said the company’s large established franchises are growing faster than in prior periods, while several newer businesses could provide additional expansion.

Cardiac rhythm management: Revenue rose 15% including the extra week, or about 9% on an adjusted basis, driven by EV-ICD, conduction system pacing and leadless pacemaker technology, according to Piéton. Spine: Piéton said the Stealth AXiS platform has helped Medtronic offer navigation, visualization and robotic-assistance tools alongside implants, supporting customer retention and pricing. Surgical: The surgical business performed well, including acute care and monitoring, he said. High-growth opportunities: Piéton identified cardiac ablation, Symplicity renal denervation for hypertension, Altaviva for urinary incontinence and Hugo surgical robotics as four potentially multibillion-dollar opportunities. Martha said Medtronic has effectively doubled its investment in innovation in recent years when both internal research and development and external investments, including venture investments and acquisitions, are considered. He said the company’s growth is diversified by geography, business line and a mix of organic and inorganic investment.

Cardiac Ablation and Robotics Expansion Cardiac ablation was a notable driver, with Martha describing the business as exceeding the company’s earlier expectation of reaching $2 billion in sales. Piéton said the market is growing at a mid-teens rate, or around 15%, and Medtronic expects to grow at more than 2.5 times the market rate for the full fiscal year. He said the company grew its capital-equipment installed base by 40% in the fourth quarter and by 35% sequentially in the first quarter, which should support future catheter demand.

Medtronic’s Sphere-9 catheter is currently a major contributor to ablation growth, Piéton said. The company has launched Sphere-360 in Europe and is conducting U.S. clinical trials. Martha said the company recently completed enrollment in the Sphere-360 trial, which includes a 12-month follow-up before submission.

On surgical robotics, Martha discussed Medtronic’s $700 million investment and distribution agreement with Cornerstone, which provides rights to the Sentire surgical robot in 50 countries outside the U.S. He said the deal broadens Medtronic’s offering in international markets, where hospitals and health systems may seek alternatives tailored to local needs and pricing.

Martha said Hugo, Medtronic’s surgical robotics platform, is focused on developed markets. The company expects to surpass 50,000 cumulative procedures and reach approximately 250 cumulative installed systems globally by year-end. Piéton said Hugo is already contributing to surgical-business growth, though the company did not provide specific revenue figures. Martha said Hugo has reached 99% uptime in the U.S. following software updates and refinements during its controlled launch.

Pipeline, Portfolio and Investor Day Martha said Medtronic sees renal denervation as a future billion-dollar product opportunity. He said the company is working to expand payer coverage and referral pathways for its hypertension therapy after a national U.S. coverage decision. He also said Medtronic plans more direct-to-consumer marketing in selected cities beginning in the fall.

Medtronic continues to evaluate tuck-in acquisitions, Piéton said, noting that the company has announced approximately $2.7 billion to $2.8 billion in deals over the last 12 months, compared with roughly $400 million to $500 million annually in the preceding six or seven years. He said the company intends to balance acquisition-related dilution with overhead leverage and improved gross margins.

The company also reiterated its intention to separate its MiniMed diabetes business. Piéton said Medtronic’s guidance assumes MiniMed remains consolidated for the full fiscal year, and that the ultimate earnings-per-share impact of a separation would depend on timing. He said MiniMed’s business performance has improved, but the intent to separate the business has not changed.

Medtronic plans to provide additional details on its growth outlook, new drivers and long-term financial framework at an Investor Day in December in Charlotte, North Carolina. Martha said the event will include demonstrations of the company’s robotics and digital technology ecosystems as well as physician perspectives.

About Medtronic (NYSE:MDT)Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Medtronic Right Now?Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against HDFC Bank Limited (“HDFC” or “the Company”) (NYSE: HDB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of HDB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: July 17, 2023 to May 26, 2026

DEADLINE: October 12, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. HDFC disguised payments as marketing costs to hide higher interest for state-controlled firms. Senior management was aware of these activities and approved them even thought they likely violated policies and regulations. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about HDFC, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE:

Schall, Brown & Schwartz LLP

LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 13, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired HDFC Bank Limited (“HDFC” or the “Company”) (NYSE: HDB) securities between July 17, 2023 and May 26, 2026 inclusive (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR HDFC BANK LIMITED INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?
On March 18, 2026, during U.S. market hours, HDFC filed a letter with the Bombay Stock Exchange and the National Stock Exchange of India Limited, reporting the resignation of Mr. Atanu Chakraborty from his roles as part-time Chairman and Independent Director of HDFC. The Company’s letter attached Mr. Chakraborty’s resignation letter, which stated that “[c]ertain happenings and practices within the bank, that I have observed over last two years, are not in congruence with my personal Values and Ethics. This is the basis of my aforementioned decision.”

On this news, the price of HDFC’s American Depositary Shares (“ADS”) fell $2.09, or 7.28% to close at $26.62 per share on March 18, 2026, on unusually heavy trading volume.

On May 27, 2026, before the market opened, The Indian Express published an article entitled “HDFC Bank ‘camouflaged’ crores as marketing spend to pay higher interest to state firm.” The article reported that HDFC Bank had made covert payments of approximately “Rs 45 crore,” or approximately $4.7 million USD, to the Maharashtra State Road Development Corporation (“MSRDC”) to induce MSRDC to make large deposits with the Company. The Company offered 6.01% interest to MSRDC, a 2.51% markup over the interest offered to other savings accounts, and paid that markup by “disguis[ing] [it] as sponsorship payments for a road safety awareness campaign run by MSRDC.” Reportedly, an internal probe in March and April 2026 concluded that over ten top officials bore responsibility, including HDFC’s CEO Sashidhar Jagdishan.

On this news, HDFC’s ADS price fell $1.02, or 4.1%, to close at $23.78 per share on May 27, 2026, on unusually heavy trading volume.

What Is The Lawsuit About?
The complaint filed in this class action alleges that between July 17, 2023 and May 26, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HDFC Bank camouflaged payments as marketing spend to pay higher interest to a state firm in order to induce deposits; (2) these activities were approved by senior management; (3) these activities likely violated regulations and the Company’s own policies, including those that prohibit payments that could constitute improper inducement; (4) as a result of the foregoing, the Company’s interest income and operating expenses were overstated; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased or otherwise acquired HDFC Bank Limited securities between July 17, 2023 and May 26, 2026, you may move the Court no later than October 13, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against HDFC Bank Limited (“HDFC” or the “Company”) (NYSE: HDB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether HDFC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until October 13, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired HDFC securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.        

[Click here for information about joining the class action]

On March 18, 2026, during U.S. market hours, HDFC filed a letter with the Bombay Stock Exchange and the National Stock Exchange of India Limited, reporting the resignation of Mr. Atanu Chakraborty from his roles as part-time Chairman and Independent Director of HDFC. The Company’s letter attached Mr. Chakraborty’s resignation letter, which stated that “[c]ertain happenings and practices within the bank, that I have observed over last two years, are not in congruence with my personal Values and Ethics. This is the basis of my aforementioned decision.” 

On this news, the price of HDFC’s American Depositary Shares (“ADS”) fell $2.09, or 7.28% to close at $26.62 per share on March 18, 2026, on unusually heavy trading volume. 

On May 27, 2026, before the market opened, The Indian Express published an article entitled “HDFC Bank ‘camouflaged’ crores as marketing spend to pay higher interest to state firm.” The article reported that HDFC Bank had made covert payments of approximately “Rs 45 crore,” or approximately $4.7 million USD, to the Maharashtra State Road Development Corporation (“MSRDC”) to induce MSRDC to make large deposits with the Company. The Company offered 6.01% interest to MSRDC, a 2.51% markup over the interest offered to other savings accounts, and paid that markup by “disguis[ing] [it] as sponsorship payments for a road safety awareness campaign run by MSRDC.” Reportedly, an internal probe in March and April 2026 concluded that over ten top officials bore responsibility, including HDFC’s CEO Sashidhar Jagdishan. 

On this news, HDFC’s ADS price fell $1.02, or 4.11%, to close at $23.78 per ADS on May 27, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

San Francisco, California--(Newsfile Corp. - September 8, 2026) - Hagens Berman, a national law firm noted for its preeminent work in securities class action litigation, notifies investors in HDFC Bank Limited (NYSE: HDB) of a pending securities fraud class action.

Class Period: July 17, 2023 - May 26, 2026Lead Plaintiff Deadline: Oct. 13, 2026Visit: www.hbsslaw.com/hdb Contact the Firm Now: [email protected] / 844-916-0895HDFC Bank Limited (HDB) Securities Class Action Overview:

The lawsuit filed against HDFC Bank Limited ("HDFC" or the "Company"), and certain top executive officers including Chief Executive Officer Sashidhar Jagdishan and Chief Financial Officer Srinivasan Vaidyanathan, alleges violations of the federal securities laws.

Specifically, the action centers on HDFC's failure to disclose key material adverse facts regarding its business operations, financial accounting, and regulatory compliance:

Camouflaged Marketing Payments & Covert Deposit Inducements: HDFC secretly funneled approximately Rs 45 crore (approx. $4.7 million USD) to the Maharashtra State Road Development Corporation ("MSRDC") to induce the state firm to place large deposits with the bank.Disguised Above-Market Interest Rates: To circumvent regulations and provide MSRDC with a 6.01% interest rate (a 2.51% markup over standard retail savings accounts), senior management devised a scheme to route the differential payments through the marketing department disguised as sponsorship contributions for a road safety awareness campaign.Governance and Regulatory Breaches: These covert practices violated the Reserve Bank of India's (RBI) Master Directions on interest rates and breached the bank's own internal anti-bribery and anti-corruption policies prohibiting improper inducements.Overstated Financials: As a result of these hidden activities, HDFC's interest income and operating expenses were overstated during the class period, rendering the Company's positive public statements and financial controls false and misleading.Truth Begins to Unravel & Stock Price Declines:

The fraudulent scheme allegedly began to surface in stages, causing sharp drops in the market value of HDFC American Depositary Shares (ADS):

March 18, 2026: HDFC announced the abrupt resignation of part-time Chairman and Independent Director Atanu Chakraborty, whose resignation letter stated that happenings and practices within the bank over the prior two years were "not in congruence with my personal Values and Ethics." On this news, HDFC ADS prices fell 7.28% on heavy volume.May 27, 2026: The Indian Express published an investigative report exposing that HDFC "camouflaged crores as marketing spend" to pay higher interest to MSRDC, revealing an internal vigilance probe implicating CEO Sashidhar Jagdishan and other top leadership. Following this disclosure, HDFC ADS fell 4.1% to close at $23.78 per share.Hagens Berman's Investigation

"We're focused on whether HDFC's senior leadership concealed a covert scheme to funnel millions in disguised payments to induce state-firm deposits while publicly painting a picture of strong governance and compliance, as the complaint alleges," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.

What Affected HDB Investors Should Do

If you purchased or acquired HDFC securities between July 17, 2023, and May 26, 2026, and suffered significant financial losses, you have until October 13, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/hdb, call Reed Kathrein at 844-916-0895, or email [email protected].

Whistleblowers: Persons with non-public information regarding HDFC should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact: Hagens Berman, Reed Kathrein, 715 Hearst Avenue, Suite 300, Berkeley, CA 94710, 844-916-0895, [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313511

Source: Hagens Berman Sobol Shapiro LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of HDFC Bank Limited (NYSE: HDB) between July 17, 2023 to May 26, 2026, inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased HDFC Bank securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the HDFC Bank class action, go to https://rosenlegal.com/cases/hdfc-bank-limited/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) HDFC Bank camouflaged payments as marketing spend to pay higher interest to a state firm in order to induce deposits; (2) these activities were approved by senior management; (3) these activities likely violated regulations and HDFC Bank’s own policies, including those that prohibit payments that could constitute improper inducement; (4) as a result of the foregoing, HDFC Bank’s interest income and operating expenses were overstated; and (5) as a result of the foregoing, defendants’ positive statements about HDFC Bank’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the HDFC class action, go to https://rosenlegal.com/cases/hdfc-bank-limited/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Key Takeaways RTX secured a contract worth up to $472M to support modernization and sustainment of the CH-47 Chinook fleet.RTX's avionics upgrades aim to add capabilities, address obsolete systems and strengthen mission readiness.RTX shares surged 32.3% in the past year, while its industry declined 6.4%, and trade below its industry P/E. RTX Corporation (RTX - Free Report) is strengthening its position in military aviation as the U.S. Army continues to modernize and sustain its helicopter fleet. Through its Collins Aerospace business, the company secured a contract worth up to $472 million to provide engineering services supporting the modernization and sustainment of the CH-47 Chinook fleet.

The contract will support avionics upgrades designed to integrate new capabilities, address obsolete systems and strengthen the Chinook’s avionics architecture. These upgrades should help maintain the fleet’s mission readiness while enabling the Army to incorporate new technologies more efficiently.

The award also supports greater commonality across the Army’s aviation fleet through the use of open and reusable avionics architectures. Such systems can be integrated across multiple aircraft, helping reduce integration complexity and improve cost and schedule efficiency as the Army modernizes its aviation platforms.

The latest award highlights Collins Aerospace’s longstanding relationship with the U.S. Army and its role in providing advanced avionics solutions for military aircraft. Continued investments in fleet modernization and technology upgrades should support demand for RTX’s avionics and mission systems.

With the U.S. military focused on extending the service lives and capabilities of existing aircraft while preparing them for evolving operational requirements, RTX is well-positioned to benefit from sustained demand for advanced avionics and modernization services. The Chinook contract strengthens RTX’s defense presence and reinforces its role in advancing the U.S. Army’s aviation modernization programs.

Defense Stocks to Keep on the RadarOther aerospace and defense companies benefiting from military aviation modernization are discussed below:

Lockheed Martin (LMT - Free Report) : Lockheed Martin provides advanced helicopters, avionics, mission systems and sustainment solutions to the U.S. military. Its Sikorsky business supports the Army’s helicopter fleet, positioning the company to benefit from continued investment in military aviation modernization.

Boeing (BA - Free Report) : Boeing’s Defense, Space & Security business supports the U.S. military with helicopters, aircraft and related sustainment services. Its strong presence in military rotorcraft positions it to benefit from ongoing fleet modernization and lifecycle support programs.

The Zacks Rundown for RTXShares of RTX have surged 30.2% in the past year against the industry’s 7% decline.

Image Source: Zacks Investment Research

The company’s shares are trading at a discount on a relative basis, with its forward 12-month Price/Earnings being 26.44X compared with its industry’s average of 30.76X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for RTX’s 2026 and 2027 earnings has moved north over the past 60 days.

Image Source: Zacks Investment Research

RTX stock currently carries a Zacks Rank #2 (Buy).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Versant Media's (VSNT.O) MS Now cable network is rolling out a membership ​program featuring live Q&A sessions, ‌allowing users to directly chat with its anchors and reporters, as the company leans ​on direct-to-consumer offerings to boost ​engagement.

The membership will be available for ⁠purchase on Apple and Google app ​stores and the MS Now website, the ​company said, adding that it would roll it out to more platforms and devices ​in the future.

Members can ask MS ​Now reporters questions through live chats with hosts ‌including ⁠Rachel Maddow and Morning Joe's Joe Scarborough at noon, as well as send in questions for newsroom reporters ​later in ​the ⁠day.

The move is the latest in Versant's push for ​growth as a standalone company ​after ⁠the CNBC owner's spin-off from Comcast (CMCSA.O). The company has been focused on ⁠driving ​digital platform growth as ​its legacy linear TV business contracts.

NOW's AI growth, strong subscription gains and broader demand are offset by stiff competition, margin pressure and a premium valuation.

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Intuit Inc. (NASDAQ: INTU) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intuit securities between August 22, 2025 and May 20, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/INTU.

Intuit Case Details

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:
      (1)   they had overstated Intuit’s competitive advantages and growth, as well as the overall strength and sustainability of its business model and operations;
      (2)   in reality, Intuit was losing significant business in its tax-related business, particularly in its TurboTax business, as a result of, inter alia, increasing competitive and pricing pressures;
      (3)   accordingly, Intuit’s previously issued FY 2026 TurboTax revenue growth guidance was unreliable and/or unrealistic; and
      (4)   as a result, Defendants’ public statements were materially false and misleading at all relevant times.

What's Next for Intuit Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/INTU. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Intuit you have until September 8, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Intuit Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Intuit Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Intuit Inc. (NASDAQ: INTU) between February 25, 2025 and June 1, 2026, inclusive (the "Class Period"), of the important September 8, 2026 lead plaintiff deadline. The Class Period was expanded to include more investors.

SO WHAT: If you purchased Intuit common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Intuit class action, go to https://rosenlegal.com/cases/intuit-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants portrayed Intuit as uniquely positioned to benefit from the rapid adoption of generative artificial intelligence ("GenAI"). Defendants further assured investors that Mailchimp, an email marketing platform Intuit had acquired in 2021, was successfully executing a turnaround and remained on track to return to double-digit growth. The lawsuit alleges that these statements were materially false and misleading because defendants concealed that GenAI was already placing significant competitive pressure on Intuit's core businesses, undermining its ability to sustain the growth, pricing, and profitability investors had come to expect. Defendants likewise concealed that Mailchimp was failing to deliver the growth and strategic benefits defendants repeatedly touted. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Intuit class action, go to https://rosenlegal.com/cases/intuit-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313375

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

INTU Deadline: Rosen Law Firm Urges Intuit Inc. (NASDAQ: INTU) Stockholders to Contact the Firm for Information About Their Rights Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Intuit Inc. (NASDAQ: INTU) between February 25, 2025 and June 1, 2026. The Class Period was expanded to include more investors. Intuit describes itself as a company that “provides financial management, payments and capital, compliance, and marketing products and services in the U.S.”

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.

The Allegations: Rosen Law Firm is Investigating the Allegations that Intuit Inc. (NASDAQ: INTU) Misled Investors Regarding its Business Operations.

According to the lawsuit, throughout the Class Period, defendants portrayed Intuit as uniquely positioned to benefit from the rapid adoption of generative artificial intelligence (“GenAI”). Defendants further assured investors that Mailchimp, an email marketing platform Intuit had acquired in 2021, was successfully executing a turnaround and remained on track to return to double-digit growth. The lawsuit alleges that these statements were materially false and misleading because defendants concealed that GenAI was already placing significant competitive pressure on Intuit’s core businesses, undermining its ability to sustain the growth, pricing, and profitability investors had come to expect. Defendants likewise concealed that Mailchimp was failing to deliver the growth and strategic benefits defendants repeatedly touted. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Intuit Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by September 8, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $2 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260908506940/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Lockheed Martin (LMT +2.07%) stock jumped 2.5% through 11:50 a.m. ET this morning.

You can thank Swiss investment bank UBS for that.

Image source: Getty Images.

Why UBS loves Lockheed stock Lockheed Martin isn't expected to report earnings again until late October, but that isn't stopping UBS from making its recommendation now: Buy Lockheed Martin stock, which costs only $538 per share but is set to reach $674 per share within a year.

UBS bases its upgrade on the belief that Lockheed's F-35 fighter jet franchise, plus missile sales, will result in "stronger and more durable earnings growth than investors currently expect," as StreetInsider.com reports today.

How much stronger? With Lockheed's book-to-bill ratio hitting a massive 3.2x in the most recent quarter, UBS sees Lockheed's sales growing 9% annually over the next 2-3 years, with earnings growth in the double-digits. This isn't an uncommon view, either. Indeed, according to data from S&P Global Market Intelligence, most analysts following Lockheed are forecasting earnings growth in the 19%- plus range over the next five years.

Premium Feature

Moneyball Superscore

78/100

Today's Change

(

2.07

%) $

10.87

Current Price

$

536.15

How to value Lockheed Martin stock And honestly, this is the time frame I'd focus on as an investor: Long-term -- five years out or more -- not just the next couple of years. As UBS points out, depleted U.S. weapons inventories should keep Lockheed Martin busy building missiles as far out as 2030 or even 2035.

Meanwhile, Lockheed Martin stock costs barely 19.2 times earning -- and less than 14 times free cash flow. Weighed against the company's 19% expected growth, and supported by a healthy 2.6% dividend yield, Lockheed Martin stock may be one of the best buys in defense today.

UBS thinks it's a buy -- and I agree.

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Lockheed Martin. The Motley Fool has a disclosure policy.

Lockheed Martin (LMT - Free Report) closed at $536.15 in the latest trading session, marking a +2.07% move from the prior day. This change outpaced the S&P 500's 0.58% loss on the day. Elsewhere, the Dow lost 1.18%, while the tech-heavy Nasdaq lost 0.32%.

Prior to today's trading, shares of the aerospace and defense company had lost 12.91% lagged the Aerospace sector's loss of 10.2% and the S&P 500's loss of 0.36%.

Analysts and investors alike will be keeping a close eye on the performance of Lockheed Martin in its upcoming earnings disclosure. The company is forecasted to report an EPS of $7.28, showcasing a 4.75% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $20.33 billion, showing a 9.27% escalation compared to the year-ago quarter.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $30.39 per share and revenue of $80.82 billion. These totals would mark changes of +31.44% and +7.7%, respectively, from last year.

Investors should also pay attention to any latest changes in analyst estimates for Lockheed Martin. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.1% higher within the past month. Lockheed Martin is currently a Zacks Rank #3 (Hold).

With respect to valuation, Lockheed Martin is currently being traded at a Forward P/E ratio of 17.28. This valuation marks a discount compared to its industry average Forward P/E of 21.9.

One should further note that LMT currently holds a PEG ratio of 1.14. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Aerospace - Defense industry had an average PEG ratio of 1.65.

The Aerospace - Defense industry is part of the Aerospace sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

NEW YORK--(BUSINESS WIRE)--The Estée Lauder Companies Inc. (NYSE: EL) today announced expanded leadership roles for two members of its Executive Team. Brian Franz has been appointed Chief Technology & Transformation Officer, expanding his responsibilities to include leading the company's enterprise-wide transformation. Amber English has been named President, Digital & Online, The Americas and Global Amazon Lead, assuming new enterprise-wide responsibility for The Estée Lauder Companies'.

Rakuten Investment Management Inc. increased its holdings in Broadcom Inc. (NASDAQ:AVGO – Free Report) by 14.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 969,839 shares of the semiconductor manufacturer’s stock after acquiring an additional 123,941 shares during the quarter. Broadcom makes up about 1.0% of Rakuten Investment Management Inc.’s investment portfolio, making the stock its 8th largest position. Rakuten Investment Management Inc.’s holdings in Broadcom were worth $361,217,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Denver PWM LLC increased its position in Broadcom by 17.5% during the 2nd quarter. Denver PWM LLC now owns 1,611 shares of the semiconductor manufacturer’s stock valued at $633,000 after purchasing an additional 240 shares during the period. Orion Capital Management LLC raised its holdings in shares of Broadcom by 16.8% in the 2nd quarter. Orion Capital Management LLC now owns 2,061 shares of the semiconductor manufacturer’s stock valued at $779,000 after purchasing an additional 296 shares in the last quarter. Liontrust Investment Partners LLP lifted its position in shares of Broadcom by 3.7% in the 2nd quarter. Liontrust Investment Partners LLP now owns 642,254 shares of the semiconductor manufacturer’s stock worth $242,611,000 after purchasing an additional 22,702 shares during the period. Glenview Trust Co purchased a new stake in shares of Broadcom in the 2nd quarter worth approximately $147,696,000. Finally, Concorde Asset Management LLC boosted its stake in shares of Broadcom by 5.5% during the second quarter. Concorde Asset Management LLC now owns 2,186 shares of the semiconductor manufacturer’s stock valued at $826,000 after purchasing an additional 114 shares in the last quarter. 76.43% of the stock is currently owned by institutional investors.

Broadcom Price Performance Shares of Broadcom stock opened at $357.89 on Tuesday. The company has a quick ratio of 2.29, a current ratio of 2.50 and a debt-to-equity ratio of 0.57. The company has a market cap of $1.70 trillion, a P/E ratio of 45.71 and a beta of 1.44. The firm’s 50 day moving average price is $383.28 and its 200-day moving average price is $377.77. Broadcom Inc. has a 52-week low of $289.96 and a 52-week high of $495.00.

Broadcom (NASDAQ:AVGO – Get Free Report) last announced its earnings results on Wednesday, September 2nd. The semiconductor manufacturer reported $3.32 earnings per share for the quarter, beating the consensus estimate of $3.22 by $0.10. Broadcom had a net margin of 42.94% and a return on equity of 48.33%. The company had revenue of $29.59 billion during the quarter, compared to the consensus estimate of $29.24 billion. During the same period last year, the firm earned $1.69 earnings per share. Broadcom’s revenue was up 85.5% compared to the same quarter last year. On average, sell-side analysts predict that Broadcom Inc. will post 10.25 EPS for the current fiscal year. Broadcom Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Monday, September 21st will be given a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Monday, September 21st. Broadcom’s dividend payout ratio is currently 33.21%.

Insiders Place Their Bets In other Broadcom news, Director Justine Page sold 1,602 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $373.86, for a total value of $598,923.72. Following the completion of the sale, the director owned 17,426 shares of the company’s stock, valued at approximately $6,514,884.36. This trade represents a 8.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gayla Delly sold 1,890 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $385.38, for a total value of $728,368.20. Following the sale, the director owned 31,326 shares in the company, valued at $12,072,413.88. The trade was a 5.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 61,644 shares of company stock valued at $24,016,214. 1.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In Several brokerages recently issued reports on AVGO. Benchmark lifted their price objective on shares of Broadcom from $485.00 to $545.00 and gave the company a “buy” rating in a report on Thursday, June 4th. Raymond James Financial restated an “outperform” rating and set a $475.00 target price (up from $450.00) on shares of Broadcom in a report on Thursday. Oppenheimer reaffirmed an “outperform” rating and set a $535.00 target price (up from $450.00) on shares of Broadcom in a research report on Thursday, June 4th. Rosenblatt Securities began coverage on Broadcom in a report on Thursday, September 3rd. They issued a “buy” rating and a $600.00 price target on the stock. Finally, Susquehanna reissued a “positive” rating and issued a $490.00 price target (up from $450.00) on shares of Broadcom in a research report on Thursday, May 28th. Thirty investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $504.93.

Get Our Latest Report on AVGO

Key Broadcom News Here are the key news stories impacting Broadcom this week:

Positive Sentiment: Broadcom raised its fiscal 2027 AI-semiconductor revenue forecast to approximately $115 billion, up from more than $100 billion previously, and reportedly sees potential for about $230 billion in fiscal 2028. The outlook reflects sustained spending by hyperscalers on custom accelerators and AI infrastructure. Broadcom’s AI Forecast Suggests Hyperscalers Want More Than Just Nvidia GPUs Positive Sentiment: AI semiconductor revenue reportedly jumped 221% to $16.7 billion in the latest quarter. Broadcom is benefiting as large technology companies seek alternatives or complements to Nvidia GPUs, particularly for inference workloads, custom silicon and high-speed data-center networking. Broadcom Inc. Stock: Rises as Custom AI Silicon Fuels Massive Growth Outlook Positive Sentiment: Analysts and financial commentators increasingly characterize Broadcom as a major beneficiary of the expansion of customized AI infrastructure, alongside its strong free-cash-flow generation and AI networking exposure. The company’s custom-chip strategy could also pressure competitors such as AMD in hyperscaler accounts. Broadcom stock: Why the AI chipmaker’s growth story is gaining steam Neutral Sentiment: High-volume purchases of Broadcom call options indicate speculative bullish interest, but options activity does not guarantee sustained buying in the shares. Stock Traders Purchase High Volume of Broadcom Call Options Negative Sentiment: Investors remain concerned about Broadcom’s premium valuation, possible margin pressure, supply constraints and dependence on a limited number of large customers. These risks help explain why the stock has declined over the past three months despite its strong AI growth outlook. Broadcom Drops 10% in 3 Months: Buy, Sell or Hold the Stock? About Broadcom (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software solutions for a broad range of markets. The company’s semiconductor business provides components and systems for wired and wireless communications, enterprise and cloud storage, networking and broadband access, serving original equipment manufacturers, cloud service providers, telecommunications carriers and industrial customers worldwide. Broadcom is headquartered in Irvine, California, and operates globally with research, development and sales organizations across North America, Europe and Asia.

On the semiconductor side, Broadcom’s portfolio includes system-on-chip (SoC) and application-specific integrated circuit (ASIC) solutions, radio-frequency and connectivity components, Ethernet switching and PHY devices, storage adapters and controllers, optical transceivers and other networking silicon.

Featured Articles Five stocks we like better than Broadcom 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding AVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Broadcom Inc. (NASDAQ:AVGO – Free Report).

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

Pin Oak Investment Advisors Inc. acquired a new position in Broadcom Inc. (NASDAQ:AVGO – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,406 shares of the semiconductor manufacturer’s stock, valued at approximately $436,000.

A number of other hedge funds also recently bought and sold shares of AVGO. Norges Bank bought a new stake in shares of Broadcom during the 4th quarter valued at $24,252,196,000. Legal & General Group Plc bought a new stake in Broadcom during the 2nd quarter worth approximately $11,998,148,000. Bank of New York Mellon Corp purchased a new position in Broadcom during the second quarter valued at approximately $10,528,191,000. Jupiter Topco LLC purchased a new position in Broadcom during the second quarter valued at approximately $7,396,271,000. Finally, Deutsche Bank AG bought a new position in shares of Broadcom in the second quarter worth approximately $5,661,216,000. Hedge funds and other institutional investors own 76.43% of the company’s stock.

More Broadcom News Here are the key news stories impacting Broadcom this week:

Positive Sentiment: Broadcom raised its fiscal 2027 AI-semiconductor revenue forecast to approximately $115 billion, up from more than $100 billion previously, and reportedly sees potential for about $230 billion in fiscal 2028. The outlook reflects sustained spending by hyperscalers on custom accelerators and AI infrastructure. Broadcom’s AI Forecast Suggests Hyperscalers Want More Than Just Nvidia GPUs Positive Sentiment: AI semiconductor revenue reportedly jumped 221% to $16.7 billion in the latest quarter. Broadcom is benefiting as large technology companies seek alternatives or complements to Nvidia GPUs, particularly for inference workloads, custom silicon and high-speed data-center networking. Broadcom Inc. Stock: Rises as Custom AI Silicon Fuels Massive Growth Outlook Positive Sentiment: Analysts and financial commentators increasingly characterize Broadcom as a major beneficiary of the expansion of customized AI infrastructure, alongside its strong free-cash-flow generation and AI networking exposure. The company’s custom-chip strategy could also pressure competitors such as AMD in hyperscaler accounts. Broadcom stock: Why the AI chipmaker’s growth story is gaining steam Neutral Sentiment: High-volume purchases of Broadcom call options indicate speculative bullish interest, but options activity does not guarantee sustained buying in the shares. Stock Traders Purchase High Volume of Broadcom Call Options Negative Sentiment: Investors remain concerned about Broadcom’s premium valuation, possible margin pressure, supply constraints and dependence on a limited number of large customers. These risks help explain why the stock has declined over the past three months despite its strong AI growth outlook. Broadcom Drops 10% in 3 Months: Buy, Sell or Hold the Stock? Broadcom Stock Performance Shares of AVGO stock opened at $357.89 on Tuesday. The business’s fifty day simple moving average is $383.28 and its 200-day simple moving average is $377.77. The company has a current ratio of 2.50, a quick ratio of 2.29 and a debt-to-equity ratio of 0.57. Broadcom Inc. has a 12-month low of $289.96 and a 12-month high of $495.00. The company has a market cap of $1.70 trillion, a PE ratio of 45.71 and a beta of 1.44. Broadcom (NASDAQ:AVGO – Get Free Report) last posted its quarterly earnings data on Wednesday, September 2nd. The semiconductor manufacturer reported $3.32 EPS for the quarter, topping the consensus estimate of $3.22 by $0.10. The business had revenue of $29.59 billion during the quarter, compared to the consensus estimate of $29.24 billion. Broadcom had a net margin of 42.94% and a return on equity of 48.33%. The business’s revenue for the quarter was up 85.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.69 earnings per share. Analysts expect that Broadcom Inc. will post 10.25 earnings per share for the current fiscal year.

Broadcom Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Monday, September 21st will be given a dividend of $0.65 per share. The ex-dividend date is Monday, September 21st. This represents a $2.60 dividend on an annualized basis and a dividend yield of 0.7%. Broadcom’s dividend payout ratio (DPR) is 33.21%.

Wall Street Analysts Forecast Growth A number of analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $515.00 price objective (up from $430.00) on shares of Broadcom in a research note on Thursday, June 4th. Rosenblatt Securities initiated coverage on Broadcom in a research note on Thursday, September 3rd. They issued a “buy” rating and a $600.00 price target for the company. Benchmark lifted their price objective on shares of Broadcom from $485.00 to $545.00 and gave the company a “buy” rating in a research report on Thursday, June 4th. The Goldman Sachs Group reiterated a “buy” rating on shares of Broadcom in a research report on Monday, August 3rd. Finally, Dbs Bank upgraded shares of Broadcom to a “moderate buy” rating in a research report on Thursday, June 18th. Thirty analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $504.93.

Check Out Our Latest Analysis on AVGO

Insiders Place Their Bets In related news, Director Gayla Delly sold 1,890 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $385.38, for a total value of $728,368.20. Following the completion of the sale, the director owned 31,326 shares of the company’s stock, valued at approximately $12,072,413.88. The trade was a 5.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Brazeal sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $401.33, for a total value of $10,033,250.00. Following the sale, the insider owned 194,989 shares of the company’s stock, valued at approximately $78,254,935.37. This trade represents a 11.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,644 shares of company stock valued at $24,016,214 in the last three months. 1.90% of the stock is currently owned by company insiders.

Broadcom Company Profile (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software solutions for a broad range of markets. The company’s semiconductor business provides components and systems for wired and wireless communications, enterprise and cloud storage, networking and broadband access, serving original equipment manufacturers, cloud service providers, telecommunications carriers and industrial customers worldwide. Broadcom is headquartered in Irvine, California, and operates globally with research, development and sales organizations across North America, Europe and Asia.

On the semiconductor side, Broadcom’s portfolio includes system-on-chip (SoC) and application-specific integrated circuit (ASIC) solutions, radio-frequency and connectivity components, Ethernet switching and PHY devices, storage adapters and controllers, optical transceivers and other networking silicon.

Further Reading Five stocks we like better than Broadcom 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding AVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Broadcom Inc. (NASDAQ:AVGO – Free Report).

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

Broadcom delivered a standout Q3, with 86% revenue growth and robust beats on both top and bottom lines, driven by AI semiconductor momentum. I maintain a Strong Buy rating and $588 price target, citing accelerating growth in both Semiconductor Solutions and Infrastructure Software, and a comfortable margin of safety versus Street estimates. AVGO's AI chip business is scaling rapidly, with secured supply supporting $115B in FY27 and $230B in FY28, underpinned by sticky hyperscaler relationships and cost advantages.

Amazon just handed Qualcomm a multi-generation AI silicon deal that sent shares surging against a falling market, but the fine print raises a pointed question about whether this credential ever becomes a revenue line.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A multi-generation AI silicon supply deal is powering Qualcomm (NASDAQ:QCOM | QCOM Price Prediction) shares in Tuesday morning trading, handing the chipmaker a marquee data-center credential well outside its handset franchise. The counterparty is Amazon (NASDAQ:AMZN), whose AWS unit will co-develop customized silicon at scale with Qualcomm for large-scale AI inference workloads. The reaction reads squarely as a Qualcomm story, which fits the shape of the announcement.

Broader benchmarks are lower: the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down 0.47%, so the chip names are climbing against a softer tape. Qualcomm stock is up 5% to $177.60 in early trading. At the same time, Broadcom (NASDAQ:AVGO) stock is rising 3% to $367.10 on read-through to the custom AI silicon category.

Amazon stock is down 1% to $255.65 as the buyer folds another silicon supplier into its AWS mix. Notably, Qualcomm stock was up 5% year to date (YTD) heading into the session, meaning today’s move accounts for essentially all of that advance. Qualcomm’s market capitalization sits near $189.7 billion against Broadcom’s $1.755 trillion, framing the scale gap between the two AI silicon stories.

Amazon Deal Validates Qualcomm’s Data-Center Push Deal details include customized silicon built for AI inference at hyperscale, plus high-performance optical connectivity that leans on Qualcomm’s SerDes and optical DSP portfolio. Qualcomm will also deepen its own use of AWS for electronic design automation workloads, which management pitches as a way to compress chip design cycles. CEO Cristiano Amon said data center infrastructure needs advances in both computing and connectivity to deliver greater performance with more efficiency.

Amon has been steering the company toward a $40 billion non-handset revenue target by fiscal 2029, with the data center as the accelerator. On the July earnings call, he guided non-handset revenue growth to accelerate from 24% in fiscal 2026 to greater than 60% in fiscal 2027, and flagged data-center revenue of $5 billion in fiscal 2027 rising to $15 billion by fiscal 2029. The Amazon collaboration appears to confirm and expand the hyperscaler custom silicon engagement Qualcomm previewed on its Q2 FY2026 call.

Broadcom’s Read-Through and the Custom Silicon Category Broadcom is the incumbent in custom AI accelerators and hyperscaler networking, so a fresh Qualcomm win could easily have been read as share migration away from the leader. Instead, Broadcom shares are climbing alongside Qualcomm, which points to broad validation of the custom silicon category across suppliers.

Broadcom’s own numbers make the demand backdrop clear. Last week, the company posted AI semiconductor revenue of $16.7 billion, up 221% year over year (YoY), and guided Q4 FY2026 AI revenue to approximately $21.7 billion. CEO Hock Tan told analysts “demand for our custom AI accelerators and networking continues to be very strong.”

The optical connectivity dimension of the Qualcomm-Amazon deal overlaps directly with Broadcom’s dominant optical DSP franchise. On its September earnings call, Broadcom management flagged Tomahawk 6 deployments at essentially every AI hyperscaler and said demand for EML and CW lasers is far outstripping industry supply, which frames the connectivity buildout as a rising-tide dynamic across suppliers (we profiled seven companies riding that same AI infrastructure buildout, from power to cooling to networking, in a free report here).

Amazon, for its part, keeps stacking silicon suppliers to lower the cost of inference and preserve customer choice. CEO Andy Jassy said on the July call that AI and Chips businesses each exceeded $25 billion annualized run rates growing triple-digit percentages, with OpenAI committing roughly 2 gigawatts of Trainium capacity and Anthropic up to 5 gigawatts. Qualcomm now joins Trainium and Graviton in the AWS chip roster, giving the lineup another optionality lever without dislodging incumbent silicon programs.

What to Watch The immediate question is whether Qualcomm’s morning gain holds into the close. The announcement didn’t carry committed volume, disclosed revenue, or a delivery timetable, and that gap is precisely what would turn a credential into an earnings line. Analyst notes on non-handset ramp acceleration should shape the next leg for Qualcomm shares.

Investors sizing their exposure to the AI silicon trade may want to watch for durability in Broadcom’s sympathy move, since the incumbent’s reaction is the cleanest read on how this deal gets framed. Furthermore, traders can keep an eye on the stock for any Amazon commentary that quantifies volumes or timelines, which would push the story from category validation toward a countable revenue line.

Given the absence of hard volume or delivery details, keeping their position sizing modest makes sense until Qualcomm quantifies the ramp. Qualcomm stock carries a P/E ratio near 33x, which already prices in some data-center optimism, so any disappointment on cadence could cool sentiment quickly.

Contact [email protected] for any questions or corrections.

Application-specific integrated circuits (ASICs) are custom chips designed to perform specific tasks, and demand for these chips has been growing at a terrific pace amid the artificial intelligence (AI) infrastructure boom.

As custom AI processors are designed exclusively to perform a specific task, they are extremely efficient at that task. This results in higher energy efficiency and improved performance over general-purpose chips, such as graphics cards. The lower cost of running AI workloads on custom chips is why major hyperscalers and AI companies have been designing in-house processors.

Marvell Technology (MRVL +0.83%) and Broadcom (AVGO +2.98%) are among the leading players in custom AI chips, which explains why they have been growing at an incredible pace. Let's take a closer look at their business and decide which of these semiconductor stocks is a better buy right now for investors looking to capitalize on the fast-growing custom AI space.

Image source: The Motley Fool.

Marvell and Broadcom dominate the custom AI chip market, but one of them is significantly bigger Counterpoint Research estimates that Broadcom will control 60% of the custom AI chip market in 2027. Marvell is a challenger to Broadcom in this space, with a market share of 20% to 25%.

Premium Feature

Moneyball Superscore

88/100

Today's Change

(

0.83

%) $

1.86

Current Price

$

225.41

Broadcom's dominant share explains why it is growing at a significantly faster pace. Its revenue in the third quarter of fiscal 2026 (which ended on Aug. 2) increased 86% year over year to $29.6 billion. Broadcom noted that its impressive growth was driven primarily by a 221% year-over-year increase in AI semiconductor revenue to $16.7 billion.

The impressive top-line growth translated into a 96% year-over-year increase in the company's earnings per share to $3.32. The good news for Broadcom investors is that the company expects its AI chip revenue to increase 236% year over year in the current quarter to $21.7 billion.

The rapid growth in Broadcom's AI chip revenue can be attributed to its solid customer base, which includes OpenAI, Anthropic, Meta Platforms, and Alphabet's Google, among others. Importantly, Broadcom predicts that its AI chip momentum will continue well beyond fiscal 2026.

Specifically, the company anticipates an increase of 186% in AI chip revenue in fiscal 2026 to $58 billion, followed by an increase of almost 2x in fiscal 2027 to $115 billion. What's more, Broadcom predicts that its AI chip revenue could jump to $230 billion in fiscal 2028. Broadcom believes that this phenomenal growth trajectory could take its earnings per share to more than $30.00 in fiscal 2028. That would be a significant improvement over the company's estimated fiscal 2026 earnings per share of $11.64.

Marvell, meanwhile, reported a 37% year-over-year increase in revenue in the second quarter of fiscal 2027 (which ended on Aug. 1) to $2.74 billion. Its earnings-per-share growth was also healthy at 40%. Though Marvell's growth is respectable, Broadcom's numbers make it clear that its dominance in custom AI chips is giving it a bigger boost.

Also, Marvell's guidance suggests it won't match Broadcom's superior growth anytime soon. The company anticipates a 45% jump in revenue in fiscal 2027 to $12 billion, followed by a 50% increase in fiscal 2028. Marvell management notes that its custom AI business is on track to more than double in fiscal 2028 and will "accelerate significantly in fiscal 2029."

So, the custom AI chip market's growth is proving to be a tailwind for Marvell, but it is easy to see that Broadcom enjoys an upper hand owing to its dominance. Also, a closer look at the valuations of both companies will further tell us why investing in Broadcom stock could be the smarter move.

Broadcom's valuation makes it a no-brainer buy Marvell stock has soared 163% in 2026, as of this writing. Broadcom, meanwhile, has been a laggard with gains of just 3%.

However, Broadcom's underperformance suggests that the market hasn't given it enough credit for its remarkable growth. That's the reason why it is significantly cheaper than Marvell.

Data by YCharts

The chart above also suggests that Broadcom's earnings per share could increase faster than Marvell's over the long run. So, investors looking to choose from these AI stocks have a simple decision to make. Broadcom's faster growth and cheaper valuation could supercharge the stock, while Marvell's relatively slower growth could weigh on its shares after a strong 2026 rally.

Shares of Broadcom (AVGO +2.98%) climbed on Tuesday, gaining as much as 4.1%. As of 2:46 p.m. ET, the stock was still up 3.1%.

The catalyst that sent the semiconductor specialist higher was a report that Intel plans to raise prices for its CPUs.

Image source: The Motley Fool.

AI adoption continues A report surfaced on Tuesday suggesting that Intel plans to raise prices later this year in a bid to boost its gross profit margin. The company plans to hike the cost of its CPUs by 10% this fall, according to a report by DigiTimes.

If true, this would mark the third round of price hikes by Intel this year, after increases in Q1 and in July.

Just last month, Nvidia reportedly notified customers of plans to raise prices by more than 15% to offset rising memory chip costs, according to a report that first appeared in Bloomberg. The increases are scheduled to take place on chips and systems shipped early next year. This will include the company's Grace Blackwell and Vera Rubin chips and will largely depend on the generation of the chips and memory configurations, according to the report.

Premium Feature

Moneyball Superscore

67/100

Today's Change

(

9.05

%) $

8.67

Current Price

$

104.47

So what does this have to do with Broadcom? The spiraling cost of high-speed memory chips has been well documented, and the impact is being felt across the artificial intelligence (AI) landscape. Many of the biggest tech players have cited the spike in memory chip prices, which are weighing on margins and pinching profits.

With major players like Intel and Nvidia announcing price increases, Broadcom has the cover to do the same. Investors have been watching closely to see whether chipmakers can maintain their juicy gross profit margins, and with memory prices on the rise, doing so hinges on raising prices.

Broadcom stock is currently selling for 32 times forward earnings and 19 times next year's expected earnings. While that might seem pricy, I'd argue it's a reasonable price to pay for a company that just increased its year-over-year revenue by 86% and AI-related revenue by 221%.

Danny Vena, CPA has positions in Broadcom and Nvidia. The Motley Fool has positions in and recommends Broadcom, Intel, and Nvidia. The Motley Fool has a disclosure policy.